Skip to main content
SpringerLink
Log in

Right Heart Failure

  • Chapter
  • First Online:
Evidence-Based Cardiology Consult

  • 1968 Accesses

Abstract

Right ventricular failure (RVF) is a frequent and formidable clinical challenge in the intensive care unit, the operating room, the general ward, and the outpatient setting. The presence of RVF (1) carries substantial morbidity and mortality and (2) complicates the use of commonly employed treatment strategies in both inpatients and outpatients. In contrast to the left ventricle (LV), the right ventricle (RV) remains relatively understudied, and none of the major professional societies have published any guidelines on how to approach patients with RVF. Due to embryological, anatomical, physiological, biochemical, and electrophysiological differences between the RV and LV, paradigms that are important for the treatment of the failing LV cannot be extrapolated to RVF. However, with pulmonary hypertension (PH) having become a major area of scientific and clinical interest, recent studies have shed more light on the physiology of the normal RV and the pathophysiology of its failure. Using a comprehensive and evidence-based approach, this chapter will (1) highlight the pathophysiology of the failing RV; (2) discuss the etiologies of acute, chronic, and acute-on-chronic RVF; (3) describe invasive and noninvasive approaches that assist in diagnosis and risk stratification; and (4) emphasize treatment strategies for stable (chronic) and decompensated (acute) RVF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Erzurum S, Rounds SI, Stevens T, et al. Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med. 2010;182(12):1554–62.

    PubMed  Google Scholar 

  2. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a national heart, lung, and blood institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114(17):1883–91.

    PubMed  Google Scholar 

  3. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I. Circulation. 2008;117:1436–48.

    PubMed  Google Scholar 

  4. Greyson CR. Pathophysiology of right ventricular failure. Crit Care Med. 2008;36(1 Suppl):S57–65.

    PubMed  Google Scholar 

  5. Garry DJ, Olson EN. A common progenitor at the heart of development. Cell. 2006;127(6):1101–4.

    PubMed  CAS  Google Scholar 

  6. Buckingham M, Meilhac S, Zaffran S. Building the mammalian heart from two sources of myocardial cells. Nat Rev Genet. 2005;6(11):826–35.

    PubMed  CAS  Google Scholar 

  7. Brown SB, Raina A, Katz D, Szerlip M, Wiegers SE, Forfia PR. Longitudinal shortening accounts for the majority of right ventricular contraction and improves after pulmonary vasodilator therapy in normal subjects and patients with pulmonary arterial hypertension. Chest. 2011;140(1):27–33.

    PubMed  Google Scholar 

  8. Klima U, Guerrero JL, Vlahakes GJ. Contribution of the interventricular septum to maximal right ventricular function. Eur J Cardiothorac Surg. 1998;14(3):250–5.

    PubMed  CAS  Google Scholar 

  9. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994;150(3):833–52.

    PubMed  CAS  Google Scholar 

  10. Brooks WW, Bing OH, Blaustein AS, Allen PD. Comparison of contractile state and myosin isozymes of rat right and left ventricular myocardium. J Mol Cell Cardiol. 1987;19(5):433–40.

    PubMed  CAS  Google Scholar 

  11. Rudolph AM. The changes in the circulation after birth. Their importance in congenital heart disease. Circulation. 1970;41(2):343–59.

    PubMed  CAS  Google Scholar 

  12. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100(9):2315–24.

    PubMed  CAS  Google Scholar 

  13. Wang GY, McCloskey DT, Turcato S, Swigart PM, Simpson PC, Baker AJ. Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium. Am J Physiol Heart Circ Physiol. 2006;291(4):H2013–7.

    PubMed  CAS  Google Scholar 

  14. Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89(3):803–15.

    PubMed  CAS  Google Scholar 

  15. Denault AY, Chaput M, Couture P, Hebert Y, Haddad F, Tardif JC. Dynamic right ventricular outflow tract obstruction in cardiac surgery. J Thorac Cardiovasc Surg. 2006;132(1):43–9.

    PubMed  Google Scholar 

  16. Lahm T, McCaslin CA, Wozniak TC, et al. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol. 2010;56(18):1435–46.

    PubMed  Google Scholar 

  17. Haddad FDR, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II. Circulation. 2008;117:1717–31.

    PubMed  Google Scholar 

  18. Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation. 1981;63(1):87–95.

    PubMed  CAS  Google Scholar 

  19. Bogaard HJ, Natarajan R, Henderson SC, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009;120(20):1951–60.

    PubMed  Google Scholar 

  20. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794–804.

    PubMed  CAS  Google Scholar 

  21. Haddad F, Ashley E, Michelakis ED. New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Curr Opin Cardiol. 2010;25(2):131–40.

    PubMed  Google Scholar 

  22. Pawlush DG, Musch TI, Moore RL. Ca2+-dependent heterometric and homeometric autoregulation in hypertrophied rat heart. Am J Physiol. 1989;256(4 Pt 2):H1139–47.

    PubMed  CAS  Google Scholar 

  23. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26(7):1581–5.

    PubMed  CAS  Google Scholar 

  24. Le RJ, Fenstad ER, Maradit-Kremers H, et al. Syncope in adults with pulmonary arterial hypertension. J Am Coll Cardiol. 2011;58(8):863–7.

    PubMed  Google Scholar 

  25. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):14S–34.

    PubMed  Google Scholar 

  26. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124(25):2865–73.

    PubMed  Google Scholar 

  27. Piazza G, Goldhaber SZ. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest. 2005;128(3):1836–52.

    PubMed  Google Scholar 

  28. ZuWallack RL, Liss JP, Lahiri B. Acquired continuous murmur associated with acute pulmonary thromboembolism. Chest. 1976;70(4):557–9.

    PubMed  CAS  Google Scholar 

  29. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113(16):2011–20.

    PubMed  Google Scholar 

  30. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313–21.

    PubMed  CAS  Google Scholar 

  31. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178(4):425–30.

    PubMed  Google Scholar 

  32. Reesink HJ, Tulevski II, Marcus JT, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2007;84(2):537–43.

    PubMed  Google Scholar 

  33. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72.

    PubMed  Google Scholar 

  34. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–33.

    PubMed  CAS  Google Scholar 

  35. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(5):534–41.

    PubMed  CAS  Google Scholar 

  36. Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008;177(9):1018–25.

    PubMed  CAS  Google Scholar 

  37. Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177(12):1364–9.

    PubMed  CAS  Google Scholar 

  38. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010;35(6):1286–93.

    PubMed  CAS  Google Scholar 

  39. Scherz N, Labarere J, Mean M, Ibrahim SA, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2010;182(9):1178–83.

    PubMed  Google Scholar 

  40. Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4(6):692–9.

    PubMed  Google Scholar 

  41. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53(14):1211–8.

    PubMed  CAS  Google Scholar 

  42. van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005;235(3):798–803.

    PubMed  Google Scholar 

  43. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034–41.

    PubMed  Google Scholar 

  44. Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med. 2011;183(2):268–76.

    PubMed  Google Scholar 

  45. Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002;20(5):1314–31.

    PubMed  CAS  Google Scholar 

  46. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S67–77.

    PubMed  Google Scholar 

  47. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–63.

    PubMed  Google Scholar 

  48. Fitzpatrick 3rd JR, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27(12):1286–92.

    PubMed  Google Scholar 

  49. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–619.

    PubMed  Google Scholar 

  50. Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185(4):400–8.

    PubMed  CAS  Google Scholar 

  51. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31(1):202–8.

    PubMed  CAS  Google Scholar 

  52. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–830.

    PubMed  Google Scholar 

  53. Heresi GA, Tang WH, Aytekin M, Hammel J, Hazen SL, Dweik RA. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur Respir J. 2012;39(4):939–44.

    PubMed  CAS  Google Scholar 

  54. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003;108(7):844–8.

    PubMed  CAS  Google Scholar 

  55. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98(3):351–60.

    PubMed  CAS  Google Scholar 

  56. Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98(3):342–50.

    PubMed  CAS  Google Scholar 

  57. Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680–4.

    PubMed  Google Scholar 

  58. Nagendran J, Michelakis E. MRI: one-stop shop for the comprehensive assessment of pulmonary arterial hypertension? Chest. 2007;132(1):2–5.

    PubMed  Google Scholar 

  59. Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. Am J Respir Crit Care Med. 2002;166(10):1310–9.

    PubMed  Google Scholar 

  60. Jardin F, Vieillard-Baron A. Monitoring of right-sided heart function. Curr Opin Crit Care. 2005;11(3):271–9.

    PubMed  Google Scholar 

  61. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–21.

    PubMed  Google Scholar 

  62. McConnell MV, Solomon SD, Rayan ME, Come PC, Goldhaber SZ, Lee RT. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol. 1996;78(4):469–73.

    PubMed  CAS  Google Scholar 

  63. Casazza F, Bongarzoni A, Capozi A, Agostoni O. Regional right ventricular dysfunction in acute pulmonary embolism and right ventricular infarction. Eur J Echocardiogr. 2005;6(1):11–4.

    PubMed  Google Scholar 

  64. Platz E, Hassanein AH, Shah A, Goldhaber SZ, Solomon SD. Regional right ventricular strain pattern in patients with acute pulmonary embolism. Echocardiography. 2012;29(4):464–70.

    PubMed  Google Scholar 

  65. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J. 1984;107(3):526–31.

    PubMed  CAS  Google Scholar 

  66. Rydman R, Soderberg M, Larsen F, Caidahl K, Alam M. Echocardiographic evaluation of right ventricular function in patients with acute pulmonary embolism: a study using tricuspid annular motion. Echocardiography. 2010;27(3):286–93.

    PubMed  Google Scholar 

  67. Badano LP, Ginghina C, Easaw J, et al. Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects. Eur J Echocardiogr. 2010;11(1):27–37.

    PubMed  Google Scholar 

  68. Park JH, Park YS, Park SJ, et al. Midventricular peak systolic strain and Tei index of the right ventricle correlated with decreased right ventricular systolic function in patients with acute pulmonary thromboembolism. Int J Cardiol. 2008;125(3):319–24.

    PubMed  Google Scholar 

  69. Dentali F, Bertolini A, Nicolini E, et al. Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. Intern Emerg Med. 2011.

    Google Scholar 

  70. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S85–96.

    PubMed  Google Scholar 

  71. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease – long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987;76(5):1037–42.

    PubMed  CAS  Google Scholar 

  72. La Vecchia L, Varotto L, Zanolla L, Spadaro GL, Fontanelli A. Right ventricular function predicts transplant-free survival in idiopathic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown). 2006;7(9):706–10.

    Google Scholar 

  73. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55–66.

    PubMed  Google Scholar 

  74. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S78–84.

    PubMed  CAS  Google Scholar 

  75. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136(1):37–43.

    PubMed  Google Scholar 

  76. Tedford RJ, Hassoun PM, Mathai SC, et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation. 2012;125(2):289–97.

    PubMed  Google Scholar 

  77. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120(11):992–1007.

    PubMed  Google Scholar 

  78. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med. 2009;37(9):2642–7.

    PubMed  Google Scholar 

  79. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555–62.

    PubMed  CAS  Google Scholar 

  80. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37(1):183–8.

    PubMed  CAS  Google Scholar 

  81. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19(1):48–54.

    PubMed  CAS  Google Scholar 

  82. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34(6):1802–6.

    PubMed  CAS  Google Scholar 

  83. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114(14):1482–9.

    PubMed  Google Scholar 

  84. McLaughlin VV, Rich S. Pulmonary hypertension. Curr Probl Cardiol. 2004;29(10):575–634.

    PubMed  Google Scholar 

  85. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250–94.

    PubMed  Google Scholar 

  86. Handoko ML, de Man FS, Happe CM, et al. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation. 2009;120(1):42–9.

    PubMed  CAS  Google Scholar 

  87. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917–28.

    PubMed  Google Scholar 

  88. Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182(5):652–60.

    PubMed  CAS  Google Scholar 

  89. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol. 1998;82(4A):9I–19.

    PubMed  CAS  Google Scholar 

  90. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.

    PubMed  CAS  Google Scholar 

  91. Drummond GA, Squire IB. The cardiac insufficiency bisoprolol study II. Lancet. 1999;353(9161):1361.

    PubMed  CAS  Google Scholar 

  92. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295–302.

    PubMed  CAS  Google Scholar 

  93. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130(1):120–6.

    PubMed  CAS  Google Scholar 

  94. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998;81(2):247–50.

    PubMed  CAS  Google Scholar 

  95. Massie B, Kramer BL, Topic N, Henderson SG. Hemodynamic and radionuclide effects of acute captopril therapy for heart failure: changes in left and right ventricular volumes and function at rest and during exercise. Circulation. 1982;65(7):1374–81.

    PubMed  CAS  Google Scholar 

  96. Cargill RI, Lipworth BJ. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest. 1996;109(2):424–9.

    PubMed  CAS  Google Scholar 

  97. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.

    PubMed  CAS  Google Scholar 

  98. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007;35(9):2037–50.

    PubMed  Google Scholar 

  99. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334(5):296–302.

    PubMed  CAS  Google Scholar 

  100. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–34.

    PubMed  CAS  Google Scholar 

  101. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–8.

    PubMed  CAS  Google Scholar 

  102. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(2):293–9.

    PubMed  CAS  Google Scholar 

  103. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.

    PubMed  CAS  Google Scholar 

  104. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529–35.

    PubMed  CAS  Google Scholar 

  105. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.

    PubMed  CAS  Google Scholar 

  106. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.

    PubMed  CAS  Google Scholar 

  107. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44–54.

    PubMed  CAS  Google Scholar 

  108. Teerlink JR. Reversal of left ventricular remodeling: role of the endothelin pathway. J Card Fail. 2002;8(6 Suppl):S494–9.

    PubMed  CAS  Google Scholar 

  109. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116(3):238–48.

    PubMed  CAS  Google Scholar 

  110. Yin J, Kukucka M, Hoffmann J, et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail. 2011;4(2):198–206.

    PubMed  CAS  Google Scholar 

  111. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105(20):2398–403.

    PubMed  CAS  Google Scholar 

  112. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8–17.

    PubMed  CAS  Google Scholar 

  113. Blum A. Treating heart failure with sildenafil. Congest Heart Fail. 2009;15(4):181–5.

    PubMed  CAS  Google Scholar 

  114. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895–900.

    PubMed  CAS  Google Scholar 

  115. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–8.

    PubMed  Google Scholar 

  116. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131(3):897–9.

    PubMed  Google Scholar 

  117. Han MK, Bach D, Hagan P, Yow E, Flaherty K, Toews G, Anstrom K, Martinez F. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. CHEST. 2013;143(6):1699–1708.

    Google Scholar 

  118. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(3):270–8.

    PubMed  CAS  Google Scholar 

  119. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet. 1996;347(8999):436–40.

    PubMed  CAS  Google Scholar 

  120. Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest. 1998;113(1):65–70.

    PubMed  CAS  Google Scholar 

  121. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619–28.

    PubMed  CAS  Google Scholar 

  122. Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol. 1999;84(6):682–6.

    PubMed  CAS  Google Scholar 

  123. Reichenberger F, Pepke-Zaba J, McNeil K, Parameshwar J, Shapiro LM. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax. 2003;58(9):797–800.

    PubMed  CAS  Google Scholar 

  124. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998;32(2):297–304.

    PubMed  CAS  Google Scholar 

  125. Olsson JK, Zamanian RT, Feinstein JA, Doyle RL. Surgical and interventional therapies for pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005;26(4):417–28.

    PubMed  Google Scholar 

  126. Hoetzenecker K, Ankersmit HJ, Bonderman D, et al. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg. 2009;137(3):760–1.

    PubMed  Google Scholar 

  127. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76(5):1457–62; discussion 1462–54.

    PubMed  Google Scholar 

  128. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007;131(4):977–83.

    PubMed  Google Scholar 

  129. Mendeloff EN, Meyers BF, Sundt TM, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg. 2002;73(1):209–17; discussion 217–9.

    PubMed  Google Scholar 

  130. Gillebert TC, Sys SU, Brutsaert DL. Influence of loading patterns on peak length-tension relation and on relaxation in cardiac muscle. J Am Coll Cardiol. 1989;13(2):483–90.

    PubMed  CAS  Google Scholar 

  131. Handoko ML, Lamberts RR, Redout EM, et al. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol. 2009;297(5):H1752–9.

    PubMed  CAS  Google Scholar 

  132. Kalogeropoulos AP, Georgiopoulou VV, Howell S, et al. Evaluation of right intraventricular dyssynchrony by two-dimensional strain echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2008;21(9):1028–34.

    PubMed  Google Scholar 

  133. Lopez-Candales A, Dohi K, Rajagopalan N, et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. Cardiovasc Ultrasound. 2005;3:23.

    PubMed  Google Scholar 

  134. Stojnic BB, Brecker SJ, Xiao HB, Helmy SM, Mbaissouroum M, Gibson DG. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. Br Heart J. 1992;68(1):16–20.

    PubMed  CAS  Google Scholar 

  135. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297(22):2502–14.

    PubMed  CAS  Google Scholar 

  136. Hardziyenka M, Surie S, de Groot JR, et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace. 2011;13(12):1753–9.

    PubMed  Google Scholar 

  137. Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011;184(10):1114–24.

    PubMed  CAS  Google Scholar 

  138. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409–17.

    PubMed  CAS  Google Scholar 

  139. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368–77.

    PubMed  CAS  Google Scholar 

  140. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818–27.

    PubMed  Google Scholar 

  141. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. New Engl J Med. 2000;342(18):1301–8.

    Google Scholar 

  142. Vieillard-Baron A, Jardin F. Why protect the right ventricle in patients with acute respiratory distress syndrome? Curr Opin Crit Care. 2003;9(1):15–21.

    PubMed  Google Scholar 

  143. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007;35:2037–50.

    PubMed  Google Scholar 

  144. Balanos GM, Talbot NP, Dorrington KL, Robbins PA. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol. 2003;94(4):1543–51.

    PubMed  Google Scholar 

  145. Bindslev L, Jolin-Carlsson A, Santesson J, Gottlieb I. Hypoxic pulmonary vasoconstriction in man: effects of hyperventilation. Acta Anaesthesiol Scand. 1985;29(5):547–51.

    PubMed  CAS  Google Scholar 

  146. Kerbaul F, Rondelet B, Motte S, et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2004;32(4):1035–40.

    PubMed  CAS  Google Scholar 

  147. Vizza CD, Rocca GD, Roma AD, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care. 2001;5(6):355–61.

    PubMed  CAS  Google Scholar 

  148. Chen EP, Bittner HB, Davis Jr RD, Van Trigt 3rd P. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg. 1997;63(3):814–21.

    PubMed  CAS  Google Scholar 

  149. Hentschel T, Yin N, Riad A, et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology. 2007;106(1):124–31.

    PubMed  CAS  Google Scholar 

  150. Solina A, Papp D, Ginsberg S, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth. 2000;14(1):12–7.

    PubMed  CAS  Google Scholar 

  151. Khazin V, Kaufman Y, Zabeeda D, et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth. 2004;18(2):156–9.

    PubMed  CAS  Google Scholar 

  152. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–89.

    PubMed  Google Scholar 

  153. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2006;34(11):2814–9.

    PubMed  CAS  Google Scholar 

  154. Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med. 2007;35(3):707–15.

    PubMed  CAS  Google Scholar 

  155. Angle MR, Molloy DW, Penner B, Jones D, Prewitt RM. The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. Chest. 1989;95(6):1333–7.

    PubMed  CAS  Google Scholar 

  156. Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest. 1995;107(4):1107–15.

    PubMed  CAS  Google Scholar 

  157. Kaisers U, Busch T, Deja M, Donaubauer B, Falke KJ. Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med. 2003;31(4 Suppl):S337–42.

    PubMed  CAS  Google Scholar 

  158. Meldrum DR, Shames BD, Meng X, et al. Nitric oxide downregulates lung macrophage inflammatory cytokine production. Ann Thorac Surg. 1998;66(2):313–7.

    PubMed  CAS  Google Scholar 

  159. Bhorade S, Christenson J, O’Connor M, Lavoie A, Pohlman A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med. 1999;159(2):571–9.

    PubMed  CAS  Google Scholar 

  160. George I, Xydas S, Topkara VK, et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg. 2006;82(6):2161–9.

    PubMed  Google Scholar 

  161. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation. 2001;72(4):638–41.

    PubMed  CAS  Google Scholar 

  162. Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg. 2005;20(2):171–6.

    PubMed  Google Scholar 

  163. Christenson J, Lavoie A, O’Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med. 2000;161(5):1443–9.

    PubMed  CAS  Google Scholar 

  164. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):35S–62.

    PubMed  Google Scholar 

  165. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31(4):891–901.

    PubMed  CAS  Google Scholar 

  166. Khan TA, Schnickel G, Ross D, et al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg. 2009;138(6):1417–24.

    PubMed  CAS  Google Scholar 

  167. Rex S, Schaelte G, Metzelder S, et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand. 2008;52(1):65–72.

    PubMed  CAS  Google Scholar 

  168. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058–67.

    PubMed  Google Scholar 

  169. Theodoraki K, Rellia P, Thanopoulos A, et al. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth. 2002;49(9):963–7.

    PubMed  Google Scholar 

  170. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth. 2008;22(3):406–13.

    PubMed  CAS  Google Scholar 

  171. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008;21(5):824–32.

    PubMed  CAS  Google Scholar 

  172. Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg. 2005;79(1):194–7; discussion 194–7.

    PubMed  Google Scholar 

  173. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90(6):677–80.

    PubMed  CAS  Google Scholar 

  174. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127(5):1647–53.

    PubMed  CAS  Google Scholar 

  175. Nagamine J, Hill LL, Pearl RG. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit Care Med. 2000;28(7):2420–4.

    PubMed  CAS  Google Scholar 

  176. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136(7):515–22.

    PubMed  CAS  Google Scholar 

  177. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91(1):307–10.

    PubMed  CAS  Google Scholar 

  178. Klodell Jr CT, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007;83(1):68–71; discussion 71.

    PubMed  Google Scholar 

  179. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest. 2005;128(4):3065–73.

    PubMed  CAS  Google Scholar 

  180. Urdaneta F, Lobato EB, Beaver T, et al. Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog. Perfusion. 2008;23(2):117–25.

    PubMed  CAS  Google Scholar 

  181. Philip A, Ramchandani S, Dorrance K, Dorrance C. Sildenafil-induced thrombocytopenia. Ann Intern Med. 2008;149(6):437–9.

    PubMed  Google Scholar 

  182. Liden H, Haraldsson A, Ricksten SE, Kjellman U, Wiklund L. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance? Eur J Cardiothorac Surg. 2009;35(6):1029–34; discussion 1034–5.

    PubMed  Google Scholar 

  183. Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg. 2007;31(4):698–702.

    PubMed  Google Scholar 

  184. Berman M, Tsui S, Vuylsteke A, Klein A, Jenkins DP. Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO? J Heart Lung Transplant. 2008;27(10):1188–9.

    PubMed  Google Scholar 

  185. Fuehner T, Kuehn C, Hadem J, et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med. 2012;185(7):763–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary Fellow, Indiana University, Pulmonary/Critical Care, 8355 Codesa Way, Indianapolis, IN, 46278, USA

    Anthony R. Cucci MD

  2. Department of Cardiology, Indiana University, 1801 N Capitol, Indianapolis, IN, 46202, USA

    M. Azam Hadi MD

  3. Division of Pulmonary, Allergy, Critical Care, Occupational, and Sleep Medicine, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA

    Tim Lahm MD

Authors
  1. Anthony R. Cucci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Azam Hadi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tim Lahm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony R. Cucci MD .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Department of Medicine,, Stony Brook University, School of Medicine,, Stony Brook, USA

    Kathleen Stergiopoulos

  2. Division of Cardiology, Stony Brook University, Stony Brook, New York, USA

    David L. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Cucci, A.R., Hadi, M.A., Lahm, T. (2014). Right Heart Failure. In: Stergiopoulos, K., Brown, D. (eds) Evidence-Based Cardiology Consult. Springer, London. https://doi.org/10.1007/978-1-4471-4441-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4441-0_22

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4440-3

  • Online ISBN: 978-1-4471-4441-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation